Gilead's Yescarta beats estimates

In its 2Q18 earnings, Gilead Sciences Inc. (NASDAQ:GILD) reported better than expected sales of CAR T cell therapy Yescarta axicabtagene ciloleucel. Sales for the drug were $68 million, beating the

Read the full 302 word article

User Sign In